Quince Therapeutics, Inc. - QNCX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 05, 2026 | SCHEDULE 13G | GROUP ONE TRADING LLC | 10.7% | 5,942,906 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Nantahala Capital Management, LLC | 9.99% | 5,620,422 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Wilmot B. Harkey | 9.99% | 5,620,422 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Daniel Mack | 9.99% | 5,620,422 | View |
| Oct 30, 2025 | SCHEDULE 13G/A | Genextra S.p.A. | 0.0% | 0 | View |
| Oct 30, 2025 | SCHEDULE 13G/A | Francesco Micheli | 0.0% | 0 | View |
| Oct 30, 2025 | SCHEDULE 13G/A | Matteo Bruno Renzulli | 0.0% | 0 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.